Clinical Trial

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-23; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07044544
Lead Sponsor University of Alabama at Birmingham
Conditions Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment 20 participants
Start Date 2025-07-17
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04